{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:55:45Z","timestamp":1760147745986,"version":"build-2065373602"},"reference-count":47,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Abbreviation of the duration of dual antiplatelet therapy (DAPT) (one or three months) has been recently proposed, especially for high bleeding risk patients, after percutaneous coronary intervention (PCI) with drug-eluting stent (DES). Three databases were screened for eligible randomized control trials. The primary endpoint was the incidence of net adverse clinical events (NACE). Secondary endpoints consisted of major adverse cardiovascular events (MACE), all-cause and cardiovascular mortality, myocardial infarction, stroke, stent-thrombosis, repeat revascularization and major bleeding. We included four RCTs with a total of 26,576 patients; 13,282 patients were grouped in 30-days DAPT, while the remaining 13,294 were allocated in a longer period of DAPT. One month of DAPT did not significantly reduce NACE (odds ratio [OR]: 0.87, 95% confidence intervals [Cl]: 0.74\u20131.03); however, major bleedings were significantly reduced by 22% (OR: 0.78, 95% Cl: 0.65\u20130.94). Mortality or ischemic events (stroke, myocardial infarction, revascularization and stent thrombosis) were not affected. Thus, 30-days DAPT could be considered as safe and feasible after PCI with DES in selected patients, especially those with high bleeding risk. Forthcoming RCTs could shed light on the optimal duration of DAPT.<\/jats:p>","DOI":"10.3390\/life13030666","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T06:09:52Z","timestamp":1677564592000},"page":"666","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Thirty-Days versus Longer Duration of Dual Antiplatelet Treatment after Percutaneous Coronary Interventions with Newer Drug-Eluting Stents: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2779-0765","authenticated-orcid":false,"given":"Grigorios","family":"Tsigkas","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Hospital of Patras, 265 04 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2616-7952","authenticated-orcid":false,"given":"Anastasios","family":"Apostolos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Patras, 265 04 Patras, Greece"},{"name":"First Department of Cardiology, University of Athens, Hippokration General Hospital, 115 27 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1596-9466","authenticated-orcid":false,"given":"David-Dimitrios","family":"Chlorogiannis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Patras, 265 04 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Bousoula","sequence":"additional","affiliation":[{"name":"Department of Cardiology, General Hospital of Piraeus \u201cTzaneio\u201d, 185 36 Piraeus, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8256-2928","authenticated-orcid":false,"given":"Georgios","family":"Vasilagkos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Patras, 265 04 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotirios","family":"Tsalamandris","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, University of Athens, Hippokration General Hospital, 115 27 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7835-793X","authenticated-orcid":false,"given":"Ioannis","family":"Tsiafoutis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Red Cross Hospital, 115 26 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Katsanos","sequence":"additional","affiliation":[{"name":"Department of Radiology, School of Medicine, University of Patras, 265 04 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Toutouzas","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, University of Athens, Hippokration General Hospital, 115 27 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel","family":"Aminian","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre Hospitalier Universitaire de Charleroi, 6042 Charleroi, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Alexopoulos","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, University of Athens, Attikon University Hospital, 124 62 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Periklis","family":"Davlouros","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Patras, 265 04 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","article-title":"ACC\/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison","volume":"72","author":"Capodanno","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","first-page":"34","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"53","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Soci","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jama.2015.1671","article-title":"Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: The dual antiplatelet therapy randomized clinical trial","volume":"313","author":"Kereiakes","year":"2015","journal-title":"JAMA"},{"key":"ref_7","first-page":"168","article-title":"Efficacy and safety of short-term (\u22646 months) duration of dual antiplatelet therapy after drug-eluting stents: A meta-analysis of randomized controlled trials","volume":"17","author":"Xiang","year":"2017","journal-title":"Anatol. J. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: A multicentre, open-la","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs. 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.jcin.2021.06.003","article-title":"1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy After Polymer-Free Drug-Coated Stent Implantation: One-Month DAPT Trial","volume":"14","author":"Hong","year":"2021","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/eurheartj\/ehm019","article-title":"Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes","volume":"28","author":"Rao","year":"2007","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/jama.2013.1556","article-title":"Association between bleeding events and in-hospital mortality after percutaneous coronary intervention","volume":"309","author":"Chhatriwalla","year":"2013","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e003519","DOI":"10.1161\/CIRCINTERVENTIONS.115.003519","article-title":"Postdischarge Bleeding After Percutaneous Coronary Intervention and Subsequent Mortality and Myocardial Infarction: Insights From the HMO Research Network-Stent Registry","volume":"9","author":"Valle","year":"2016","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Pelliccia, F., Gragnano, F., Pasceri, V., Cesaro, A., Zimarino, M., and Calabr\u00f2, P. (2022). Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133574"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10741-021-10133-6","article-title":"Heart failure and atrial fibrillation: New concepts in pathophysiology, management, and future directions","volume":"27","author":"Tsigkas","year":"2021","journal-title":"Heart Fail. Rev."},{"key":"ref_21","first-page":"352","article-title":"Anticoagulation for atrial fibrillation in heart failure patients: Balancing between Scylla and Charybdis","volume":"18","author":"Tsigkas","year":"2021","journal-title":"J. Geriatr. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/eurheartj\/ehr204","article-title":"Bleeding in acute coronary syndromes and percutaneous coronary interventions: Position paper by the Working Group on Thrombosis of the European Society of Cardiology","volume":"32","author":"Steg","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/S0140-6736(15)60292-6","article-title":"Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: A randomised multicentre trial","volume":"385","author":"Valgimigli","year":"2015","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.hjc.2020.02.002","article-title":"Transradial access through the anatomical snuffbox: Results of a feasibility study","volume":"62","author":"Tsigkas","year":"2021","journal-title":"Hellenic J. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcin.2021.09.037","article-title":"Distal or Traditional Transradial Access Site for Coronary Procedures: A Single-Center, Randomized Study","volume":"15","author":"Tsigkas","year":"2022","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/eurheartj\/ehz104","article-title":"Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction","volume":"40","author":"Sehested","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.jacc.2011.12.024","article-title":"A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers","volume":"59","author":"Frelinger","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.recesp.2020.03.013","article-title":"Very short dual antiplatelet therapy after PCI and new DES: A meta-analysis of 5 randomized trials","volume":"74","author":"Verdoia","year":"2021","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ehjcvp\/pvaa001","article-title":"Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35,785 patients undergoing percutaneous coronary interventions: A meta-analysis of randomized controlled trials","volume":"7","author":"Benenati","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40256-022-00559-0","article-title":"Very short versus longer dual antiplatelet treatment after coronary interventions: A systematic review and meta-analysis","volume":"23","author":"Tsigkas","year":"2022","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Apostolos, A., Trigka, A., Chlorogiannis, D., Vasilagkos, G., Chamakioti, M., Spyropoulou, P., Karamasis, G., Dimitriadis, K., Moulias, A., and Katsanos, K. (2022). Thirty-days versus standard duration of dual antiplatelet treatment after percutaneous coronary interventions: A systematic review and meta-analysis. Eur. Heart J., 43.","DOI":"10.1093\/eurheartj\/ehac544.2717"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2021.11.028","article-title":"Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes","volume":"15","author":"Laudani","year":"2022","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/ccd.30467","article-title":"Three versus 12-month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials","volume":"100","author":"Selvaraj","year":"2022","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_37","first-page":"3111840","article-title":"Dual Antiplatelet Therapy in Patients Aged 75 Years and Older with Coronary Artery Disease: A Meta-Analysis and Systematic Review","volume":"2022","author":"Croix","year":"2022","journal-title":"J. Interv Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJMoa1910021","article-title":"Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk","volume":"382","author":"Windecker","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.jcin.2021.07.016","article-title":"3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation","volume":"14","author":"Mehran","year":"2021","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Montalto, C., Costa, F., Leonardi, S., Micari, A., Oreglia, J.A., Vranckx, P., Capodanno, D., Berg, J.T., Lopes, R.D., and Valgimigli, M. (2022). Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials. Eur. Heart J.-Cardiovasc. Pharmacother., pvac065.","DOI":"10.1093\/ehjcvp\/pvac065"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Costa, F., Montalto, C., Branca, M., Hong, S.J., Watanabe, H., Franzone, A., Vranckx, P., Hahn, J.Y., Gwon, H.C., and Feres, F. (2022). Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: A meta-analysis of randomized trials. Eur. Heart J., ehac706.","DOI":"10.1093\/eurheartj\/ehac706"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): An investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"key":"ref_43","first-page":"2487","article-title":"Aspirin vs. Clopidogrel for Chronic Maintenance Monotherapy after Percutaneous Coronary Intervention: The HOST-EXAM Extended Study","volume":"397","author":"Kang","year":"2022","journal-title":"Circulation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/j.jcin.2022.08.009","article-title":"P2Y12 Inhibitor or Aspirin Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention","volume":"15","author":"Greco","year":"2022","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_45","first-page":"26","article-title":"Imaging of Left Main Coronary Artery; Untangling the Gordian Knot","volume":"24","author":"Apostolos","year":"2023","journal-title":"RCM"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.31083\/j.rcm2402039","article-title":"Intracoronary Imaging: Current Practice and Future Perspectives","volume":"24","author":"Tsigkas","year":"2023","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Apostolos, A., Chlorogiannis, D., Vasilagkos, G., Katsanos, K., Toutouzas, K., Aminian, A., Alexopoulos, D., Davlouros, P., and Tsigkas, G. (2023). Safety and efficacy of shortened dual antiplatelet therapy after complex percutaneous coronary intervention: A systematic review and meta-analysis. Hell. J. Cardiol.","DOI":"10.1016\/j.hjc.2023.01.005"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/3\/666\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:44:11Z","timestamp":1760121851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/3\/666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["life13030666"],"URL":"https:\/\/doi.org\/10.3390\/life13030666","relation":{},"ISSN":["2075-1729"],"issn-type":[{"type":"electronic","value":"2075-1729"}],"subject":[],"published":{"date-parts":[[2023,2,28]]}}}